|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM19767965X |
| 003 |
DE-627 |
| 005 |
20250211123201.0 |
| 007 |
tu |
| 008 |
231223s2010 xx ||||| 00| ||chi c |
| 028 |
5 |
2 |
|a pubmed25n0659.xml
|
| 035 |
|
|
|a (DE-627)NLM19767965X
|
| 035 |
|
|
|a (NLM)20426949
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Chen, Jing
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Outcome of 46 children with refractory leukemia treated with unrelated donor hematopoietic stem cell transplantation
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.02.2011
|
| 500 |
|
|
|a Date Revised 10.12.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a OBJECTIVE: To evaluate the efficacy of matched unrelated donor hematopoietic stem cell transplantation (UDT) and influencing factors in children with refractory leukemia
|
| 520 |
|
|
|a METHOD: Retrospective analysis was performed on clinical data of 46 consecutive children received UDT between Nov. 2002 and Dec. 2008. A 12-14 GY fractioned total body irradiation (TBI) was given to children with acute lymphoblastic leukemia (ALL). Busulphan based myeloablative regimen was applied to all the other patients. ATG (Fresenius) 15 - 20 mg/kg + low dose cyclosporine A oral [CSA, 8 - 12 mg/(kg * d) with serum trough levels 150 - 200 ng/ml] +/- methotrexate (without methotrexate for cord blood transplant) were administered as graft versus host disease (GVHD) prophylaxis. Mycophenolate mofetil [MMF, 20 - 30 mg/(kg * d)] was added for 13 CML after Jan 1, 2006 because of more severe GVHD was observed in this group
|
| 520 |
|
|
|a RESULTS: The median age was 8.0 (2 - 17) years with the median follow up period of 23.5 (0.7 - 85) months. The estimated 3 years overall survival (OS) was 63.0%; 23.9% patients died of transplant related mortality, 13.0% patients died of leukemia relapse. Cytomegalovirus (CMV) infection recurred in 50% patients and hemorrhagic cystitis in 15.2% patients; 33.3% patients developed grade III-IV acute GVHD and 55.6% developed chronic GVHD (13.9% with extensive chronic GVHD). The OS was significantly different between the patients older (n = 20) and younger (n = 26) than 10 years (45.0% vs. 76.9%, P = 0.015) and among the patients with ALL (n = 13), CML (n = 18) and AML (n = 15) (38.4%, 66.7% vs.80.0%, P = 0.034). The OS in patient with high risk leukemia (n = 24) was lower than that in the patient with low risk leukemia (n = 22) (45.8% vs. 81.8%, P = 0.012). Except 8 cord blood transplant the OS of patients with HLA 6/6 high resolution completely matched (n = 16) and 1/6 mismatched (n = 16) bone marrow and peripheral blood stem cell transplants was significantly higher than patients with 2/6 mismatched (n = 6) UDT (75.0%, 75.0% vs. 16.7%, P = 0.007). But the OS was not significantly different between patients with grade 0-II acute GVHD and III-IV acute GVHD (60.0% vs. 66.7%, P = 0.494)
|
| 520 |
|
|
|a CONCLUSION: The outcome of UDT for Chinese children with refractory leukemia is encouraging. Patients younger than 10 years with 0-1/6 high resolution mismatched UDT had the best OS. The outcome of patients with myeloid and low risk leukemia is superior to those with other types of leukemia
|
| 650 |
|
4 |
|a Evaluation Study
|
| 650 |
|
4 |
|a Journal Article
|
| 700 |
1 |
|
|a Luo, Cheng-juan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Hua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Chang-ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xue, Hui-liang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, Jing-yan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pan, Ci
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dong, Lu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Min
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ye, Qi-dong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yao-ping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Long-jun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 48(2010), 3 vom: 29. März, Seite 170-4
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
| 773 |
1 |
8 |
|g volume:48
|g year:2010
|g number:3
|g day:29
|g month:03
|g pages:170-4
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 48
|j 2010
|e 3
|b 29
|c 03
|h 170-4
|